pPA202
pPA202
规格:
货期:
编号:TS182894
品牌:Testobio
| 产品名称： | pPA202 |
|---|---|
| 商品货号： | TS182894 |
| Designations： | pPA202 |
| GenBank Number： | M15518 |
| Species： | Homo sapiens, human |
| Depositors： | Berlex Laboratories, Inc., L Cashion, Berlex Laboratories, Inc. |
| Applications： | in another host, produces protein plasminogen activator, tissue |
| Vector： | Construct size (kb): 13.39999961853027 |
| Insert： | DNA: cDNA Insert lengths(kb): 3.299999952316284 Gene product: plasminogen activator, tissue PLAT Target Gene: plasminogen activator, tissue |
| Insert Size (kb)： | 3.300 |
| Media： | ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Comments： | Restriction digests of the clone give the following sizes (kb): BamHI--5.8, 4.4, 3.2; BglII--6.6, 5.2, 1.6; HindIII--13.5. The portion of the construct encoding PLAT consists of a genomic BclI/BglII fragment (approximately 2.3 kb) beginning in the intron 5 to the initiation AUG, and extending through an intron into the region encoding the mature polypeptide. The rest of the PLAT sequences are derived from a 1.97 kb BglII cDNA fragment encoding the complete processed polypeptide. PLAT expression is regulated by the LTR, the mutant dhfr by an SV40 early promoter, and G418 resistance by a thymidine kinase promoter. The dhfr-IV mutation decreases enzyme affinity for methotrexate and permits resistance to higher levels of the drug. The order of the major features in this plasmid is: SV40 polyadenylation - |
| References： | Cashion L, et al. Transfected cells containing plasmids having genes oriented in opposing directions and methods of using. US Patent 5,017,478 dated May 21 1991 |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
pPA202
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | pPA202 |
|---|---|
| 商品货号： | TS182894 |
| Designations： | pPA202 |
| GenBank Number： | M15518 |
| Species： | Homo sapiens, human |
| Depositors： | Berlex Laboratories, Inc., L Cashion, Berlex Laboratories, Inc. |
| Applications： | in another host, produces protein plasminogen activator, tissue |
| Vector： | Construct size (kb): 13.39999961853027 |
| Insert： | DNA: cDNA Insert lengths(kb): 3.299999952316284 Gene product: plasminogen activator, tissue PLAT Target Gene: plasminogen activator, tissue |
| Insert Size (kb)： | 3.300 |
| Media： | ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Comments： | Restriction digests of the clone give the following sizes (kb): BamHI--5.8, 4.4, 3.2; BglII--6.6, 5.2, 1.6; HindIII--13.5. The portion of the construct encoding PLAT consists of a genomic BclI/BglII fragment (approximately 2.3 kb) beginning in the intron 5 to the initiation AUG, and extending through an intron into the region encoding the mature polypeptide. The rest of the PLAT sequences are derived from a 1.97 kb BglII cDNA fragment encoding the complete processed polypeptide. PLAT expression is regulated by the LTR, the mutant dhfr by an SV40 early promoter, and G418 resistance by a thymidine kinase promoter. The dhfr-IV mutation decreases enzyme affinity for methotrexate and permits resistance to higher levels of the drug. The order of the major features in this plasmid is: SV40 polyadenylation - |
| References： | Cashion L, et al. Transfected cells containing plasmids having genes oriented in opposing directions and methods of using. US Patent 5,017,478 dated May 21 1991 |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
